• 1
    The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:24132445.
  • 2
    The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial of prevention of stroke in isolated systolic hypertension. J Clin Epidemiol. 1988;41:11971208.
  • 3
    Liebson PR, Grandits GA, Dianzumbe S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study. Circulation. 1995;1995:698706.
  • 4
    Henderson SO, Coetzee GA, Ross RK, et al. Elevated mortality rates from circulatory disease in African-American men and women of Los Angeles County, California—a possible genetic susceptibility? Am J Med Sci. 2000;320:1823.
  • 5
    Wild SH, Laws A, Fortmann SP, et al. Mortality for coronary heart disease and stroke for six ethnic groups in California, 1985–1990. Ann Epidemiol. 1995;5:432439.
  • 6
    Fumo MT, Teeger S, Lang RM, et al. Diurnal blood pressure variation and cardiac mass in American blacks and whites and South African blacks. Am J Hypertens. 1992;5:111116.
  • 7
    Sempos C, Cooper R, Kovar MG, et al. Divergence of the recent trends in coronary mortality for the four major race-sex groups in the United States. Am J Pub Health. 1988;88:14221427.
  • 8
    Davey Smith G, Neaton JD, Wentworth D, et al. Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for the MRFIT. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Lancet. 1998;351:934939.
  • 9
    Wood A. Racial differences in the response to drugs-pointers to genetic differences. N Engl J Med. 2001;344:13931395.
  • 10
    Schwartz RS. Racial profiling in medical research. N Engl J Med. 2001;344:13921393.
  • 11
    He J, Whelton PK. Epidemiology and prevention of hypertension. Med Clin North Am. 1997;81:10771081.
  • 12
    Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol. 2000;151:346357.
  • 13
    Gibbs CR, Beevers DG, Lip GYH. The management of hypertensive disease in black patients. QJM. 1999;92:187192.
  • 14
    Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. N Engl J Med. 2000;342:905912.
  • 15
    Kshirsagar AV, Joy MS, Hogan SL, et al. Effect of ACE inhibitors in diabetic and non-diabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis. 2000;35:695707.
  • 16
    Taylor AA, Sunthornyothin S. The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers. Curr Hypertens Rep. 1999;1:446453.
  • 17
    Young CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med. 2000;343:15451552.
  • 18
    Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared to white patients with left ventricular dysfunction. N Engl J Med. 2001;344:13511357.
  • 19
    Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:13581365.
  • 20
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342;145153. 2.
  • 21
    Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354: 17511756.
  • 22
    Norris SL, de Guzman M, Sobel E, et al. Risk factors and mortality among black, Caucasian and Latina women with acute myocardial infarction. Am Heart J. 1993;126:13121319.
  • 23
    Roehrborn CG, Oesterling JE, Auerbach S, et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology. 1996;47:159168.
  • 24
    Lowe FC, Olson PJ, Padley RJ. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Urology. 1999;54:8185.
  • 25
    ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 2000;283:19671975.
  • 26
    Henderson SO, Bretsky P, Henderson BE, et al. Risk factors for cardiovascular and cerebrovascular death among African Americans and Hispanics in Los Angeles, California. Acad Emerg Med. 2001;8:11631172.
  • 27
    The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med. 1993;153:154183.